Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1513382 | 0.98 | TACR1 (0.54) | TACR1OPRM1HTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL28511334 | 0.90 | OPRM1 (0.49) | TACR1OPRM1HTR2ASLC6A4KCNH2 | |
| SCHEMBL17861568 | 0.89 | HTR2A (0.53) | TACR1OPRM1HTR2ASLC6A4KCNH2 | |
| SCHEMBL15955086 | 0.85 | MAOA (0.60) | OPRM1SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL21770897 | 0.85 | TACR1 (0.53) | TACR1OPRM1HTR2ASLC6A4KCNH2 | |
| SCHEMBL5266493 | 0.82 | TACR1 (0.55) | TACR1OPRM1HTR2ASLC6A4KCNH2 | |
| SCHEMBL9330358 | 0.81 | DPP4 (0.63) | SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL10606137 | 0.81 | DPP4 (0.57) | OPRM1SLC6A4MAOAMAOBTAAR1 | |
| SCHEMBL8042316 | 0.81 | DRD2 (0.55) | TACR1SLC6A4KCNH2 | |
| SCHEMBL20977731 | 0.81 | CYP19A1 (0.44) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2507228-B1 | NOVEL SPIROPIPERIDINE COMPOUNDS | LILLY CO ELI (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-101973998-A | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARM INC | 2011-02-16 | — | — | CN | disclosed |
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| CN-1816551-A | Pyrrolopyrimidine A2bSelective antagonist compounds, their synthesis and use | OSI PHARM INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1307458-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2003-05-07 | — | — | EP | disclosed |
| EP-1198464-A1 | 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2002-04-24 | — | — | EP | disclosed |
| WO-2002012246-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001007441-A1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-02-01 | — | — | WO | disclosed |
| US-3936464-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | TACR1 93/4885OPRM1 14/4885HTR2A 115/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | TACR1 51/4885OPRM1 30/4885HTR2A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.